Latest filing published 05 Mar 2026 for Amneal Pharmaceuticals, Inc.. Read the official filing
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Tasos Konidaris (senior executive) discloses dealings in Amneal Pharmaceuticals, Inc. to SEC (Form 4). Between 1 March 2022 and 3 March 2026, the trades on record add up to 12 filings.
The open-market record consists of 2 sales worth €2.1M, with no purchase. Other entries cover 10 option exercises.
The latest filing, published on 5 March 2026, reports an option exercise in Amneal Pharmaceuticals, Inc. Filings reach the SEC (Form 4) feed a median of 2 days after the trade. The legal deadline for a Form 4 is two business days after the transaction. A sale on its own says little: insiders also sell to pay tax, fund a purchase or diversify. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
12 of 12 declarations